Insulin–Leptin–Visceral Fat Relation During Weight Loss

Yip, Ian; Go, Vay Liang W.; Hershman, Jerome M.; Wang, He-Jing; Elashoff, Robert M.; DeShields, Scott; Liu, Yong; Heber, David

doi:10.1097/00006676-200108000-00010

Cited by 19 publications

(14 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In a recent meta-analysis, modest weight reduction has also been shown to improve glucose intolerance [33]. Similarly, sibutramine treatment is associated with significant improvement in the insulin sensitivity indexes [14][15][16][17][18][19]. In the present study, we also detected a significant improvement in the HOMA-IR index after 3 and 12 months of sibutramine treatment.…”

Section: Discussionsupporting

confidence: 80%

“…In recent literature, sibutramine has enabled a 7% reduction in initial weight after 1 year of therapy [11][12][13]. Generally, sibutramine treatment is associated with significant improvement in the insulin sensitivity, serum leptin and hsCRP [14][15][16][17][18][19]. On the other hand, it has also been demonstrated that metformin, an antihyperglycemic agent, decreases hyperinsulinemia and the insulin resistance leading to decreased adiposity in obese and noninsulin-dependent diabetes mellitus [20,21].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Comparison of the effects of sibutramine versus sibutramine plus metformin in obese women

et al. 2009

View full text Add to dashboard Cite

Sibutramine and metformin are drugs commonly used to obtain weight loss. We aimed to compare the effects of sibutramine alone with that of sibutramine plus metformin combination on weight loss, insulin sensitivity, leptin and C reactive protein in obese women. Seventy obese women were included. After a diet period of month (baseline), each individual was randomly assigned to receive 15 mg sibutramine (sibutramine group; n = 36) or 15 mg sibutramine plus 1,700 mg metformin per day (sibutramine plus metformin group; n = 34) during the next 12 months. Body weight, insulin resistance by the homeostasis model assessment model (HOMA-IR), leptin and C reactive protein were measured at baseline, after 3 months and after 12 months. Mean weight losses in sibutramine and sibutramine plus metformin groups were 5.3 +/- 4.0% (P < 0.001) and 6.8 +/- 3.9% (P < 0.001) after 3 months, and 10.5 +/- 4.4% (P < 0.001) and 15.7 +/- 4.6% (P = 0.007) after 12 months, respectively. HOMA-IR value also decreased in both sibutramine (P = 0.045 and P = 0.002) and sibutramine plus metformin groups (P = 0.04 and P = 0.015) after 3 and 12 months, respectively. Similarly, serum leptin levels decreased in both sibutramine (P = 0.04, P = 0.01) and sibutramine plus metformin groups (P = 0.023, P = 0.025) after 3 and 12 months, respectively. There was also significant reductions in serum C reactive protein levels in both sibutramine (P = 0.045, P = 0.02) and sibutramine plus metformin groups (P = 0.007, P = 0.001) after 3 and 12 months, respectively. These decrements of body weight, HOMA-IR, serum leptin and C reactive protein levels were not statistical significance between these two groups both after 3 and 12 months (P > 0.05). Combination of sibutramine with metformin did not result in any further effects on weight loss, insulin resistance, leptin and C reactive protein levels when compared to sibutramine alone.

show abstract

Section: Discussionsupporting

confidence: 80%

Section: Introductionmentioning

confidence: 99%

Comparison of the effects of sibutramine versus sibutramine plus metformin in obese women

et al. 2009

View full text Add to dashboard Cite

show abstract

“…6,71 Increasing evidence of the biological role of VAT adds greatly to the strength of the conclusion that %dV/%dS is greatest during rapid weight loss with VLCDs or modest weight loss. Many studies have shown preferential improvement in hormonal and metabolic function occurs soon after modest weight loss and/or exercise, 60,72 indicating a tight association of obesity comorbidity on neutral or positive energy balance. Perhaps early preferential loss of visceral fat is physiological, driven by an immediate need for energy, in the face of acute negative energy intake, from a metabolically active fat store uniquely situated up stream from the liver.…”

Section: Discussionmentioning

confidence: 99%

Factors associated with percent change in visceral versus subcutaneous abdominal fat during weight loss: findings from a systematic review

2008

View full text Add to dashboard Cite

Background: Visceral adipose tissue (VAT) is associated with greater obesity-related metabolic disturbance. Many studies have reported preferential loss of VAT with weight loss. Objective: This systematic review looks for factors associated with preferential loss of VAT relative to subcutaneous abdominal fat (SAT) during weight loss. Design: Medline and Embase were searched for imaging-based measurements of VAT and subcutaneous abdominal adipose tissue (SAT) before and after weight loss interventions. We examine for factors that influences the percentage change in VAT versus SAT (%dV/%dS) with weight loss. Linear regression analyses were performed on the complete data set and on subgroups of studies. Factors examined included percentage weight loss, degree of caloric restriction, exercise, initial body mass index (BMI), gender, time of follow-up and baseline VAT/SAT. Results: There were 61 studies with a total of 98 cohort time points extracted. Percentage weight loss was the only variable that influenced %dV/%dS (r ¼ À0.29, P ¼ 0.005). Modest weight loss generated preferential loss of VAT, but with greater weight loss this effect was attenuated. The method of weight loss was not an influence with one exception. Very-low-calorie diets (VLCDs) provided exceptional short-term (o4 weeks) preferential VAT loss. But this effect was lost by 12-14 weeks. Conclusions: Visceral adipose tissue is lost preferentially with modest weight loss, but the effect is attenuated with greater weight loss. Acute caloric restriction, using VLCD, produces early preferential loss of VAT. These observations may help to explain the metabolic benefits of modest weight loss.

show abstract

“…Weight loss through diet alone or diet and exercise interventions results in elevations [29][30][31][32][33][34][35][36][37][38][39] or no change [35,40] in adiponectin levels and reductions in leptin levels [29][30][31][32][33][34][35][36][37][38][39] in obese healthy individuals. On the other hand, only one study to date has examined resistin levels after weight loss [41].…”

Section: Introductionmentioning

confidence: 99%

Effects of diet and/or exercise on the adipocytokine and inflammatory cytokine levels of postmenopausal women with type 2 diabetes

et al. 2005

View full text Add to dashboard Cite

Insulin–Leptin–Visceral Fat Relation During Weight Loss

Cited by 19 publications

References 40 publications

Comparison of the effects of sibutramine versus sibutramine plus metformin in obese women

Comparison of the effects of sibutramine versus sibutramine plus metformin in obese women

Factors associated with percent change in visceral versus subcutaneous abdominal fat during weight loss: findings from a systematic review

Effects of diet and/or exercise on the adipocytokine and inflammatory cytokine levels of postmenopausal women with type 2 diabetes

Contact Info

Product

Resources

About